U.S. patent application number 14/264238 was filed with the patent office on 2014-08-21 for external patches containing etofenamate.
This patent application is currently assigned to TEIKOKU SEIYAKU CO., LTD.. The applicant listed for this patent is DROSSAPHARM AG, TEIKOKU SEIYAKU CO., LTD.. Invention is credited to Tomohiro ISHIMA, Masahiro YAMAJI, Hiroyuki YAMASAKI.
Application Number | 20140234396 14/264238 |
Document ID | / |
Family ID | 34959649 |
Filed Date | 2014-08-21 |
United States Patent
Application |
20140234396 |
Kind Code |
A1 |
ISHIMA; Tomohiro ; et
al. |
August 21, 2014 |
EXTERNAL PATCHES CONTAINING ETOFENAMATE
Abstract
The present invention provides to patches having excellent
skin-permeability and therapeutic effect by the drug with lower
irritation. In an external patch in which an adhesive layer
containing an adhesive base and a drug are laminated with a
backing, the external patch wherein the adhesive base contains
5-50% by weight of synthetic rubber polymer, 10-60% by weight of
adhesive resin and 25-60% by weight of liquid paraffin, and the
drug is etofenamate. According to the present invention, there is
obtainable the patches having excellent skin-permeability and
therapeutic effect by the drug with lower irritation.
Inventors: |
ISHIMA; Tomohiro; (Kagawa,
JP) ; YAMASAKI; Hiroyuki; (Kagawa, JP) ;
YAMAJI; Masahiro; (Kagawa, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
TEIKOKU SEIYAKU CO., LTD.
DROSSAPHARM AG |
Kagawa
Basel |
|
JP
CH |
|
|
Assignee: |
TEIKOKU SEIYAKU CO., LTD.
Kagawa
JP
DROSSAPHARM AG
Basel
CH
|
Family ID: |
34959649 |
Appl. No.: |
14/264238 |
Filed: |
April 29, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11793231 |
Jun 15, 2007 |
8747885 |
|
|
PCT/JP04/19143 |
Dec 15, 2004 |
|
|
|
14264238 |
|
|
|
|
Current U.S.
Class: |
424/449 ;
514/535; 514/536 |
Current CPC
Class: |
A61K 47/18 20130101;
A61K 47/14 20130101; A61K 9/7053 20130101; A61P 29/00 20180101;
A61K 9/7076 20130101; A61K 31/245 20130101; A61K 31/24
20130101 |
Class at
Publication: |
424/449 ;
514/535; 514/536 |
International
Class: |
A61K 31/24 20060101
A61K031/24; A61K 47/18 20060101 A61K047/18; A61K 47/14 20060101
A61K047/14; A61K 9/70 20060101 A61K009/70 |
Claims
1. In an external patch in which an adhesive layer containing an
adhesive base and a drug are laminated with a backing, the external
patch wherein the adhesive base contains 5-50% by weight of
synthetic rubber, 10-60% by weight of adhesive resin and 25-60% by
weight of liquid paraffin, and the drug is etofenamate.
2. The external patch according to claim 1 wherein the synthetic
rubber is styrene-isoprene-styrene block copolymer.
3. The external patch according to claim 1 wherein the adhesive
resin is an alicyclic saturated hydrocarbon resin.
4. The external patch according to claim 1 wherein the adhesive
layer further contains a plasticizer.
5. The external patch according to claim 4, wherein the plasticizer
is crotamiton or isopropyl myristate.
6. The external patch according to claim 2 wherein the adhesive
layer further contains a plasticizer.
7. The external patch according to claim 3 wherein the adhesive
layer further contains a plasticizer.
8. The external patch according to claim 6, wherein the plasticizer
is crotamiton or isopropyl myristate.
9. The external patch according to claim 7, wherein the plasticizer
is crotamiton or isopropyl myristate.
Description
TECHNICAL FIELD
[0001] The present invention relates to an external patch in which
an adhesive layer containing the adhesive base and the drug are
laminated with a backing.
BACKGROUND ART
[0002] Etofenamate, a non-steroidal anti-inflammatoric analgesic,
is used as a therapeutic agent for pains caused by stiff shoulders
and muscle weariness, contusion, distortion and so on in form of
ointments and gels. However, in regard to the ointments and the
gels, the control of the amount to be administered is difficult,
and as a volatile alcohol is mixed in the preparations,
skin-irritation and peculiar smell thereby have been become
problematic. Furthermore, when using the preparations, there is
such a demerit that hands or clothes are apt to dirty.
[0003] To make up for such demerits of the preparations, there is a
report on patches in which a synthetic rubber is used. For example,
in Japanese patent publication A 63-246327, are described patches
which contain etofenamate as a drug, styrene-isoprene-styrene block
copolymer (SIS block copolymer), an adhesive resin, liquid
paraffin, liquid gum and an antioxidant. However there is a room to
improve the dermal permeability of etofenamate and skin-irritation
in the patches.
DISCLOSURE OF INVENTION
[0004] The object of the present invention is to provide an
external patch which is excellent in skin-permeability of
etofenamate, has excellent anti-inflammatory activity and that is
very low in skin-irritation.
BRIEF DESCRIPTION OF DRAWINGS
[0005] FIG. 1 shows the amounts of cumulatively permeated
etofenamate in various patches.
SUMMARY OF THE INVENTION
[0006] The present inventors have been earnestly studied in order
to resolve the above disadvantages, and as a result, have found
that the patches to meet the object can be prepared by adding
etofenamate to the adhesive base containing 5-50% by weight of a
synthetic rubber, 10-60% by weight of an adhesive resin and 25-60%
by weight of liquid paraffin.
[0007] Namely the present invention relates to in an external patch
in which an adhesive layer containing the adhesive base and the
drug are laminated with a backing, the external patch wherein the
adhesive base contains 5-50% by weight of a synthetic rubber,
10-60% by weight of an adhesive resin and 25-60% by weight of
liquid paraffin, and the drug is etofenamate.
MODE FOR CARRYING OUT THE INVENTION
[0008] The synthetic rubber used in dermally absorbable patches of
the present invention includes styrene-isoprene-styrene block
copolymer (SIS block copolymer), polyisobutylene, isoprene rubber,
styrene-butadiene-styrene block copolymer, silicon rubber, etc. The
synthetic rubber may be used in a combination with them, but SIS
block copolymer is most preferable in consideration of
skin-permeability of the drug and physical property of the
preparation.
[0009] The amount of the synthetic rubber is usually 5-50% by
weight, preferably 5-40% by weight, and more preferably 10-25% by
weight. When being less than 5% by weight, the base is not
aggregated and there is a possibility that a part of the adhesive
agent remains on skin when the preparation is released from skin.
When being over 50% by weight, the aggregation power becomes too
strong and the decrease of adhesivity occurs. Therefore, it becomes
difficult to carried out the spreading step of the base due to the
high viscosity of the adhesive agent in the preparing the
preparation.
[0010] The adhesive resin is usually to provide the patch
adhesivity to skin, and rosin resin and its derivative (rosin,
rosin ester, hydrogenated rosin, hydrogenated rosin esters),
petroleum resin (alicyclic hydrocarbon resin, aliphatic hydrocarbon
resin), terpene resin, etc, are used as the adhesive resin. In the
present invention, preferably petroleum resin, especially
preferably, alicyclic saturated hydrocarbon are used from the
viewpoint of dermal absorbability and skin-adhesivity.
[0011] The amount of the adhesive resin is 10-60% by weight,
preferably 15-50% by weight, and more preferably 20-40% by weight.
When being less than 10% by weight, the adhesivity of the patch
extremely decreases. When being beyond 60% by weight, the
adhesivity becomes too strong and therefore, when releasing the
patch from skin, the physical stimulation occurs and the viscosity
of the adhesive agent becomes too high.
[0012] The liquid paraffin have the property to make soft the
adhesive agent and to improve the stickiness to skin in application
and as well, to control the adhesivity to skin and to reduce the
physical irritation to skin.
[0013] The amount of the liquid paraffin has very important role in
the preparations of the present invention.
[0014] The amount of the liquid paraffin is 25-60% by weight,
preferably 25-50% by weight, and more preferably 30-40% by weight.
When being less than 25% by weight, the adhesivity becomes too
strong, and when releasing the patch from skin, the physical
irritation occurs. Furthermore, skin-permeability of the drug
extremely reduces (see FIG. 1). When being beyond 60% by weight,
the sufficient adhesivity is not attained and the aggregation power
of the adhesive agent reduces. Therefore, there is a possibility to
remain a part of the adhesive agent to skin.
[0015] It was also found that in the preparation of the present
invention, by further adding a plasticizer to the adhesive base,
skin-permeability of the drug can be enhanced.
[0016] The plasticizer used in the present invention includes
triacetin, crotamiton, fatty acid esters such as diethyl sebacate,
triethyl citrate, isopropyl myristate, etc., N-methylpyrolidone,
etc.
[0017] The amount of the plasticizer is usually 0.5-20% by weight,
preferably 1-10% by weight, and more preferably 3-7% by weight. The
plasticizer may be used in a combination of them. A combination of
crotamiton and isopropyl myristate is especially preferable as the
plasticizer used in the present invention.
[0018] The amount of crotamiton is preferably 0.5-5% by weight.
When being less than 0.5% by weight, the effect of it is lessen.
When being beyond 5% by weight, the destruction of the aggregation
of the adhesive agent occurs and a part of the adhesive agent
remains on skin when releasing the patch from skin. The amount of
isopropyl myristate is preferably 0.5-15% by weight. When being
less than 0.5% by weight, the effect of it is lessen. When being
beyond 15% by weight, the destruction of the aggregation of
adhesive agent occurs and a part of the adhesive agent remains on
skin when releasing it from skin. The ratio of crotamiton and
isopropyl myristate is preferably 1:1-1:3 when used in their
combination.
[0019] The amount of etofenamate used in the present invention is
usually 1-10% by weight, preferably 2-8% by weight, and more
preferably 3-6% by weight. When being less than 1% by weight, the
amount of the drug released is lessen, there is a high possibility
not to attain the desired therapeutic effect, and when being beyond
10% by weight, it becomes difficult to prepare the preparation in
relation to the other ingredients.
[0020] The patches of the present invention may contains, if
necessary, other ingredients, which are usually used in the
patches, such as antioxidants, fillers, preservatives, softeners,
etc.
[0021] The antioxidant includes dibutyl hydroxytoluene, its
derivative, tocopherol, its derivative, ascorbic acid, its
derivative, etc. The filler includes calcium carbonate, magnesium
carbonate, magnesium sulfate, zinc oxide, titanium oxide, silicic
acid and its salt (silicon dioxide, aluminum silicate, magnesium
silicate, light silicic anhydride, etc.), etc. The preservative
includes parabens (p-hydroxybenzoates), etc. The softener includes
petroleum oils (paraffin oil, aromatic oil, etc.), silicon oil,
liquid rubbers (polybutene, liquid isoprene rubber, etc.), high
molecular weight fatty acids, high molecular weight fatty acid
esters, polyhydric alcohols (polyethylene glycol, propylene glycol,
diethylene glycol, cyclopropylene glycol, glycerin, glycol
salicylate, etc.), vegetable oils (olive oil, eucalyptus oil),
etc.
[0022] The thickness of the adhesive layer of the patches of the
present invention is not limited and is preferably 20-500 .mu.m,
and more preferably 70-300 .mu.m as when being too thin the
adhesivity reduces and when being too thick, the patches are
readily released by rubbing with clothes.
[0023] The backing to be used in the present invention is
preferably in being rich in flexibility, and includes, many kinds
of woven textile, unwoven textile, a vinyl chloride film, a
polyethylene film, a polyurethane film, etc. or a complexed film
laminated these films.
[0024] The release liner to be used in the present invention
includes films, such as polyethylene terephthalate (PET),
polypropylene, polyethylene chloride, etc., and these films may be,
if necessary treated by silicon to have them suitable
releasability.
[0025] The patches of the present invention are prepared as
follows.
[0026] Namely a synthetic rubber, an adhesive resin, liquid
paraffin, a softener, an antioxidant, a filler, etc. were dissolved
under heating. After cooled, etofenamate, and if necessary a
plasticizer, are added thereto and the mixture is kneaded under
stirring. Thus obtained base is spread on a silicon-treated PET
film, laminated with a backing (polyester textile) and cutting a
desired size to prepare the dermally absorbable patches of the
present invention.
[0027] The present invention is more concretely explained by the
following examples, but the present invention is not limited by
them.
[0028] The term "part" in the examples means "part by weight", if
it is not defined otherwise.
[0029] According to the method mentioned above, dermally absorbable
patches having ingredients shown in Example 1 to Example 5 were
prepared.
[0030] A preparation (patch) containing ingredients of Example 5
except liquid paraffin (5 parts) instead of etofenamate (5.0 parts)
was also prepared as a control preparation.
Example 1
TABLE-US-00001 [0031] Etofenamate 5.0 (parts) SIS block copolymer
15.0 Hydrogenated rosin glycerin ester 30.0 Liquid paraffin 38.0
Polybutene 10.0 Dibutyl hydroxytoluene 1.0 Light silicic anhydride
1.0 Total 100.0
Example 2
TABLE-US-00002 [0032] Etofenamate 5.0 (parts) SIS block copolymer
15.0 Alicyclic saturated hydrocarbon 30.0 Liquid paraffin 38.0
Polybutene 10.0 Dibutyl hydroxytoluene 1.0 Light silicic anhydride
1.0 Total 100.0
Example 3
TABLE-US-00003 [0033] Etofenamate 5.0 (parts) SIS block copolymer
15.0 Alicyclic saturated hydrocarbon 30.0 Liquid paraffin 33.0
Polybutene 10.0 Isopropyl myristate 5.0 Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0 Total 100.0
Example 4
TABLE-US-00004 [0034] Etofenamate 5.0 (parts) SIS block copolymer
15.0 Alicyclic saturated hydrocarbon 30.0 Liquid paraffin 36.0
Polybutene 10.0 Crotamiton 2.0 Dibutyl hydroxytoluene 1.0 Light
silicic anhydride 1.0 Total 100.0
Example 5
TABLE-US-00005 [0035] Etofenamate 5.0 (parts) SIS block copolymer
15.0 Alicyclic saturated hydrocarbon 30.0 Liquid paraffin 31.0
Polybutene 10.0 Isopropyl myristate 5.0 Crotamiton 2.0 Dibutyl
hydroxytoluene 1.0 Light silicic anhydride 1.0 Total 100.0
[0036] A mixture of SIS block copolymer, hydrogenated terpene
resin, liquid paraffin, polybutene and an anti-oxidant was stirred
under heating. After cooled, etofenamate was added thereto and the
mixture was kneaded under stirring. Thus obtained base was spread
on a silicon-treated PET film, laminated with a backing (polyester
textile) and cutting a desired size to prepare a patch containing
ingredients of the Comparative example 1.
Comparative Example 1*
TABLE-US-00006 [0037] Etofenamate 10.0 (parts) SIS block copolymer
30.0 Hydrogenated terpene resin 45.0 Liquid paraffin 4.5 Polybutene
10.0 Anti-oxidant 0.5 Total 100.0
*: Example 2 of Japanese patent publication A 63-24632
[0038] Etofenamate was added to acrilic polymer and thereto was
added a suitable amount of ethyl acetate in order to control the
viscosity on spreading to prepare an acrilic adhesive liquid. The
acrilic adhesive liquid was spread on a PET film, and the solvent
was removed on drying to prepare an adhesive layer. The layer was
laminated with a backing prepared by laminating a PET unwoven
textile and a PET film to prepare a patch containing ingredients of
Comparative example 2.
Comparative Example 2
TABLE-US-00007 [0039] Etofenamate 5.0 (parts) Acrylic adhesive
agent 95.0 Total 100.0
[0040] Etofenamate and isopropyl myristate were added to acrilic
polymer, and the mixture was dealt in accordance with the method of
Comparative example 2 to prepare a patch containing ingredients of
Comparative example 3.
Comparative Example 3
TABLE-US-00008 [0041] Etofenamate 5.0 (parts) Acrilic adhesive
agent 90.0 Isopropyl myristate 5.0 Total 100.0
[0042] Etofenamate and crotamiton were added to acrilic polymer,
and the mixture was dealt in accordance with the method of
Comparative example 2 to prepare a patch containing ingredients of
Comparative example 4.
Comparative Example 4
TABLE-US-00009 [0043] Etofenamate 5.0 (parts) Acrilic adhesive
agent 93.0 Crotamiton 2.0 Total 100.0
[0044] Etofenamate, isopropyl myristate and crotamiton were added
to acrilic polymer, and the mixture was dealt in accordance with
the method of Comparative example 2 to prepare a patch containing
ingredients of Comparative example 5.
Comparative Example 5
TABLE-US-00010 [0045] Etofenamate 5.0 (parts) Acrilic adhesive
agent 88.0 Isopropyl myristate 5.0 Crotamiton 2.0 Total 100.0
[0046] Test 1: Skin-Permeability Test In Vitro
[0047] In order to investigate skin-permeability of etofenamate,
skin-permeability test in vitro (rat) was carried out by using the
preparations of Examples 1, 2, 3, 4 and 5 and Comparative examples
1, 2, 3, 4 and 5. After removal of hairs of the abdomen of rats,
the skin of the abdomen was taken out and fixed in a Frantz
diffusion cell. In the inner part of the cell, phosphate buffered
physiological saline was filled as a receptor solution. Water of
37.degree. C. was cyclized in a jacket over the cell. Each patch
was punched in a circle having diameter 2.5 cm and each circle was
applied on the skin on the cell. The sampling from the receptor
solution was carried out from time to time and the amount of
etofenamate permeated through the skin was measured by liquid
chromatography.
[0048] The result was shown in FIG. 1. According to the result, the
preparation containing synthetic rubber was superior to the
preparation containing acrilic adhesive agent in skin-permeability
of etofenamate. In addition by making synthetic rubber contain the
amount in more than 25% of liquid paraffin, skin-permeability of
etofenamate was raised, and by adding crotamiton and isopropyl
myristate thereto, skin-permeability was further raised.
[0049] Test 2: Inhibition Test on Edema Induced on Plantar of Limb
by Carrageenin
[0050] Each patch of Examples 2 to 5, Comparative examples 1 and 2
was cut in a size of 3 cm.times.4 cm and the cut patch was applied
on a plantar of a right hind limb of a rat on 4 hours before
administration of carrageenin. One percent Carrageenin
physiological saline (0.1 mL) was subcutaneously administered to
the plantar of the right hind limb of the rat in order to induce
edema on that region. Before administration and 4 hours later after
administration, the volume of the limb was measured. The inhibition
rate of edema was calculated according to the following calculation
formula:
Formula:
[0051] Rate of edema(%)={(volume of limb at 4 hours later after
induction of edema (mL)-volume of limb before induction of edema
(mL))/volume of limb before induction of edema (mL)}.times.100
Inhibition rate(%)={1-rate of edema of test sample(%)/rate of
untreated control group(%)}.times.100
[0052] The result was shown in Table-1. All the preparations of the
present invention (Examples 2 to 5) showed the inhibition of edema,
especially the preparation containing crotamiton and isopropyl
myristate showed statistically significant difference comparing
with the control preparation in the inhibition of edema (Student's
t-test p<0.01).
TABLE-US-00011 TABLE 1 Sample Rate of edema (%) Rate of inhibition
(%) Untreated 59.0 .+-. 2.4 -- Control 58.9 .+-. 3.7 0.17 Example 2
48.1 .+-. 2.9 18.5 Example 3 42.0 .+-. 3.8 28.8 Example 4 35.8 .+-.
2.0 39.3 Example 5 26.5 .+-. 1.7 55.1 Comparative example 1 52.4
.+-. 4.5 11.2 Comparative example 2 54.6 .+-. 3.3 7.46
[0053] Test 3: Adhesive Test
[0054] In accordance with JIS 20237 14: slant ball-tack method,
each preparation was measured on its adhesive power. Each patch of
Example 1, Example 2, Example 5, Comparative example 1, Comparative
example 2 and Comparative example 5 was cut in a size of 10
cm.times.5 cm. The slant angle of the apparatus was set at
30.degree. C. and the slant plate made of acrilic polymer was used,
and the length of the run way and the measured part was 10 cm. The
measurement was three times per each preparation and the maximum
number among the number of balls which stayed for more than 5
minutes at the measured part was counted.
[0055] The result was shown in Table-2. The preparation containing
synthetic rubber was superior to the preparation containing acrilic
adhesive agent in adhesive power, and the adhesive power of the
preparation containing further liquid paraffin (more than 25%) was
improved.
TABLE-US-00012 TABLE 2 Sample Adhesive power Example 1 22 Example 2
22 Example 5 24 Comparative example 1 18 Comparative example 2 16
Comparative example 5 16
[0056] Test 4: Primary Skin-Irritation Test on Rabbit
[0057] This test was carried out using Japanese white female
rabbits (8 rabbits). After removal of hairs of the back of a
rabbit, each two patches were applied to right and left sides,
respectively. The right side was healthy part and the left side was
injured part. The injured part was injured in the shape of # by a
needle for injection. Each patch of Control, Example 2, Example 5,
Comparative example 1, Comparative example 2 and Comparative
example 5 (n=6) was punched in a circle of a diameter having 2.5 cm
and each of them was applied to the objected regions. Each applied
part was fixed by a tape (band-aid, trade name). The rabbits were
further wore with a protecting clothe to prevent the move of the
patches applied. Twenty four hours later after application, each
patch was removed, and the skin-reaction was observed on 1 hour, 24
hours and 48 hours.
[0058] The judgment was conducted in accordance of the judgment
standard of Draize described in Table-3. Based on the judgment at 1
hour and 48 hours after removal of patches, the index of primary
skin-irritation (P. I. I) was calculated.
[0059] The result was shown in Table-4. The preparations of the
present invention used in this test were lower in the
irritation.
TABLE-US-00013 TABLE 3 Standard of judgment of Draize Item of
observation and degree Erythema No erythema 0 and scab Slight
erythema (barely distinctive) 1 Clear erythema 2 Middle to strong
erythema 3 Strong erythema with slight scab (deeply injured) 4
Edema No edema 0 Slight edema (barely distinctive) 1 Slight edema
(outline of swelling being clear) 2 Middle ranked edema (swelling
being to about 3 1 mm height) Heavily ranked edema (swelling being
to more 4 than 1 mm height and being enlarged to outside of region
applied)
TABLE-US-00014 TABLE 4 Average score of irritation reaction (n = 6)
Sample State of skin After 1 hour After 48 hours P.I.I. Control
Normal 0.3 0 0.3 Injured 0.7 0 Example 2 Normal 0.5 0 0.4 Injured
0.8 0.3 Example 5 Normal 0.2 0 0.2 Injured 0.5 0 Comparative Normal
1.2 0.7 1.0 example 1 Injured 1.3 1.0 Comparative Normal 1.5 0.5
1.3 example 2 Injured 2.0 0.5 Comparative Normal 1.3 1 1.2 example
5 Injured 1.3 0.7
[0060] It was confirmed by the above tests that the dermally
absorbable external patches containing etofenamate as an active
ingredient of the present invention have excellent
skin-permeability and excellent therapeutic effect by etofenamate
and as well, have a higher safety and lower irritation.
* * * * *